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Primum non nocere in immunopreventive trials in diabetes
I would like to share with you some of my concerns 
regarding intervention trials among patients with auto-
immune type 1 diabetes. Among diabetologists, who 
deal with type 1 diabetes, there is still a need for an 
effective preventive therapy for the patients with per-
sisted residual insulin secretion and individuals who are 
genetically at risk of developing diabetes. Many clinical 
intervention trials were performed using for instance 
cyclosporine, insulin, antiCD3 and CD20 antibodies and 
GAD vaccine as immunomodulating agents. Some time 
ago also Polish group from Gdansk applied in the clinic 
the protocol of immunopreventive trial using expanded 
autologous CD4+CD25highCD127- T regulatory cells 
(Tregs). This study has indicated that the administra-
tion of Tregs is able to prolong the clinical remission 
in DM1 children but the clinical improvement persists 
as long as increased Tregs numbers are present in 
peripheral blood. The other recent trials showed also 
beneficial outcomes in preserving residual beta-cell 
function in new onset type 1 diabetes subjects but these 
effects were not long lasting. This is disappointing not 
only for medical community but especially for patients 
and family members seeking for a cure of autoimmune 
diabetes. Participation in the preventive trials might 
be even harmful for the patients since they could lose 
a motivation for further standard insulin treatment. 
Thus, this should be also considered during recruitment 
procedures. Another population for immune interven-
tions is a group individuals who are genetically at risk of 
developing diabetes and who are positive for multiple 
anti-islet antibodies. For this goal the TrialNet initiative 
has recently modified definition of the autoimmune 
type diabetes adding two preclinical phases as a target 
population for immune intervention. During the last the 
ADA meeting in San Diego highly visible session on type 1 
diabetes immune intervention trials took place. Prof. 
Desmond Schatz presented results of the TrialNet oral 
insulin trials showing significantly more than one-year 
delay in clinical manifestation of diabetes among sub-
jects who were treated with insulin. Two other papers 
revealed some mild beneficial effects of imatinib and 
GAD-vaccine. However, infant genetic screening for 
type 1 diabetes raises parent anxiety when the child is at 
increased risk. Persistence of anti-islet antibodies results 
heighten parent anxiety, and parents faced with two or 
more types of autoantibodies results may experience 
considerable anxiety for longer periods. This is an ad-
ditional possible injurious outcome of the intervention 
trials in diabetes. Drawing the conclusion based on the 
ADA session, this has been attributed to an incomplete 
understanding of the complex etiopathogenesis of the 
disease. Many have also suggested that monotherapeu-
tic agents, as has been the norm in most of the recent 
clinical trials, may not be as efficacious as synergistic 
combinations of immunotherapeutic agents targeting 
multiple keypoints of the immune system. However, 
beneficial effects on the course of diabetes of the tri-
als should also consider psychological aspects, which 
might be harmful of the individuals with type 1 diabetes 
and their families.
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